A Clinical Study To Evaluate The Therapeutic Effect Of Shubhdeep Liv-Gud Pill In The Management Of Yakrutdalyodara W.S.R to Fatty Liver Disease.
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- 2) Relief in anorexia.
研究概览
简要总结
In ayurveda there are 8 types of UDARA-ROGA have been described, in Ayurveda agnidosha and malavrudhi are resion of UDARA-ROGA. If there is suppresion of agni especially jatharagni, due to faulty life style, as a result of which dosha get accumulated in the kostha. This cause vitiation of Pranavayu, Jatharagni, and Apanavayu. As liver play important part of digestion, become enlarge due to vitiation of Agani and Dosha. Yakrutdalyodara developed due to vitiation of Kapha leads to mandagni caused by the continous intake of vidahi and abhishyandi aahara. The sign and symptoms of yakrutdalodara are closely related to Fatty liver. According to line of treatment of Yakrutdalyodara the SHUBHDEEP LIV-GUD PILL is selected. Its prepration have been reported to possess liver protection effect. This study is carried out in one group with pre -test and post -test design where in a minimum 30 patient suffering from Yakrutdalyodara of either sex between the age group of 20 - 60 years will be selected for the study. Final assessment of result is made on the basis of subjective & objective criteria. Appropriate statistical tests will applied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 20.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patient presenting with clinical feature of yakrutdalyodara(Fatty liver).
- •Patient with or without the clinical feature of yakrutdalyodara, diagnosed to be having USG whole abdomen where include for the study.
- •Patient age between 20-60 years with either sex.
- •Patient of alcoholic addiction, obesity, type-2 diabetes mellitus.
排除标准
- •Patient aged less than 20 yr and more than 60 years.
- •Patient with hepatic encephalopathy, systemic multiorgan syndrom, malignency of liver and cirrhosis of liver and prehepatic and hepatic coma, bleeding disorder, etc.
- •Pregnent women.
- •Hepatitis B and C.
- •Patient on steroid treatment.
结局指标
主要结局
2) Relief in anorexia.
时间窗: 45th day.
3) Relief in indigestion.
时间窗: 45th day.
4) Relief in weakness.
时间窗: 45th day.
5) Relief in fever.
时间窗: 45th day.
1) Improve power of digestion.
时间窗: 45th day.
6) Relief in constipation.
时间窗: 45th day.
次要结局
未报告次要终点